https://empagliflozininhibitor.....com/bilateral-gradi
RESULTS GFF provided significant lung purpose improvements at Week 24 versus placebo, GP, and FF for NMT patients, with pre-dose trough FEV1 treatment differences of 152 (117-188) mL, 73 (45-10 mL, and 56 (29-84) mL, respectively (minimum squares mean differ from baseline versus comparators [95% CI]; all P less then 0.0001). GFF reduced the possibility of CID by 17-43% in NMT (P ≤ 0.0157) and 18-52% (P ≤ 0.0012) in MT customers compared to monotherap
Like
Comment
Share
